Tikva Allocell Pte. Ltd. has closed an $8 million series A financing to support its development of engineered, allogeneic cell therapies for adult and pediatric patients with solid tumors.
Advancell Co. Ltd. has raised an oversubscribed $315 million series D round to accelerate its push to become a fully integrated global radiopharma developer, funding late-stage clinical development alongside isotope supply and manufacturing infrastructure.
Advancell Co. Ltd. has raised an oversubscribed $315 million series D round to accelerate its push to become a fully integrated global radiopharma developer, funding late-stage clinical development alongside isotope supply and manufacturing infrastructure.
Chinese researchers have published data regarding XYD-113, a potent and selective GSPT1 degrader intended for potential use in the management of MYC-driven cancers.
Androgen receptor (AR) signaling remains the central molecular driver of prostate cancer, sustaining tumor growth and contributing to the development of resistance to current therapies.
Flare Therapeutics Inc. has closed an $85 million series C financing and completed a strategic review of its pipeline, with funds being channeled to advance the prioritized programs.
Prostate cancer is a leading cause of cancer-related deaths among men and is a cancer type that shows genomic heterogeneity and several molecular alterations. By analyzing available microarray and next-generation transcriptome sequencing data, researchers at the University of Alabama at Birmingham found that thyroid hormone receptor-interacting protein 13 (TRIP13), a member of the AAA ATPase family, was overexpressed in prostate cancer, making it a potential therapeutic target.
Uniquest Pty Ltd., the commercialization company of the University of Queensland, has entered into an exclusive license agreement with the Ellison Medical Institute (EMI) to develop and commercialize the University of Queensland’s QED-203 for metastatic castration-resistant prostate cancer.
Shanghai Henlius Biotech Inc.’s HLX-3902, a trispecific antibody targeting STEAP1xCD3xCD28, has received approval from the Human Research Ethics Committee (HREC) in Australia and has been filed with the Therapeutic Goods Administration (TGA). The T-cell engager is intended for the treatment of metastatic castration-resistant prostate cancer and other advanced solid tumors.
